Genetics, genomics and proteomics

12S135: State-of-the-Art: Lupus State of the Art: Biomarkers Genetics and Phenotyping

Moderator(s)

• AA

  Anca Askanase, MD, MPH

  Director
  Columbia University Medical Center
  New York, NY, United States

  Disclosure(s): Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Aurinia: Advisor or Review Panel Member (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
• 

  Diane Kamen, MD, MS

  Medical University of South Carolina
  Charleston, SC, United States

  Disclosure(s): No financial relationships to disclose

Review how advances in knowledge of lupus pathogenesis, including genetics and biomarkers, are informing new approaches to lupus management.

Presentations:

• 3:30 PM – 4:15 PM Eastern Time

  Heterogeneity in SLE and Implications for Management
  

  Speaker: Joan T. Merrill, MD – Oklahoma Medical Research Foundation
• 4:15 PM – 4:30 PM Eastern Time

  Q&A